Responses
Regular and Young Investigator Award Abstracts
Biomarkers, Immune Monitoring and Novel Technologies
145 Nadunolimab inhibits IL-1α/β-induced CXCR1/2 ligand expression and reduces serum levels of CXCL1 and CXCL5 in NSCLC and PDAC patients
Compose a Response to This Article
Other responses
No responses have been published for this article.